Perceptive Advisors’s Seres Therapeutics MCRB Stock Holding History

Perceptive Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-125,000	Closed	-$8.05M	–	116
2019 Q2	$8.05M	Buy	+125,000	New	+$11.9M	0.18%	72
2017 Q4	–	Sell	-6,750	Closed	-$2.17M	–	145
2017 Q3	$2.17M	Buy	+6,750	New	+$1.84M	0.08%	92
2016 Q3	–	Sell	-77	Closed	-$45K	–	211
2016 Q2	$45K	Buy	+77	New	+$45.2K	﹤0.01%	160
2015 Q3	–	Sell	-2,500	Closed	-$2.08M	–	174
2015 Q2	$2.08M	Buy	+2,500	New	+$2.18M	0.13%	101

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors's MCRB Position: Q3 2019 in Review

Perceptive Advisors sold out of Seres Therapeutics (MCRB) in Q3 2019, closing a stake of 125,000 shares — an estimated $8.05M sold.

Perceptive Advisors first reported a position in MCRB in Q2 2015 and held it in 4 quarters. The position peaked at $8.05M in Q2 2019. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2019.

Perceptive Advisors reported no remaining Seres Therapeutics position as of Q3 2019 after selling out during the quarter.
Perceptive Advisors sold 125,000 Seres Therapeutics shares in Q3 2019, an estimated $8.05M.
Perceptive Advisors first reported a position in Seres Therapeutics in Q2 2015 and held it in 4 quarters.
Perceptive Advisors's Seres Therapeutics position peaked at $8.05M in Q2 2019.
77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2019.

Based on Perceptive Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.